Dermata Therapeutics, Inc. Common Stock (DRMA) Stock Price

DRMAStock
$0.86−78.45%52W
Market Cap$4.26M
P/E—
PEG Ratio—
Div yield—
Beta0.59

DRMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-41.11%
Price vs S&P 500 (4W)-23.89%
VGM Score33.24

DRMA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.55-$0.74-34.55%(-$0.19)
Q1 2026-$0.53-$0.48+9.43%(+$0.05)
Q4 2025-$1.54-$1.52+1.30%(+$0.02)
Q3 2025-$1.59-$1.65-3.77%(-$0.06)
Q2 2025-$2.90-$1.66+42.76%(+$1.24)

DRMA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
DRMADermata Therapeutics, Inc. Common Stock
——D————$0.86
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Dermata Therapeutics, Inc. Common Stock

Dermata Therapeutics develops OTC dermatology treatments for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment leveraging its proprietary Spongilla technology platform for enhanced delivery and patient compliance. Dermata plans to expand Spongilla's application across dermatologic and aesthetic markets, including intradermal delivery of botulinum toxin, providing multiple revenue opportunities.